Wells Fargo
BCTX

Wells Fargo’s Briacell Therapeutics BCTX Stock Holding History

Wells Fargo’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4 Hold
1
– – ﹤0.01% 7037
2025
Q4 		$7 Hold
1
– – ﹤0.01% 6923
2025
Q3 		$11 Sell
1
-2
-67% -$21 ﹤0.01% 6820
2025
Q2 		$94 Hold
3
– – ﹤0.01% 6485
2025
Q1 		$116 Buy
3
+1
+50% +$48 ﹤0.01% 6360
2024
Q4 		$164 Hold
2
– – ﹤0.01% 6381
2024
Q3 		$360 Buy
+2
New +$225 ﹤0.01% 6190

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Wells Fargo's BCTX Position: Q1 2026 in Review

Wells Fargo held its Briacell Therapeutics (BCTX) position steady in Q1 2026 at 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #7037.

Wells Fargo first reported a position in BCTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $360 in Q3 2024. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Wells Fargo held 1 share of Briacell Therapeutics worth $4 as of Q1 2026.
  • Wells Fargo left its Briacell Therapeutics share count unchanged in Q1 2026.
  • Briacell Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #7037 holding.
  • Wells Fargo first reported a position in Briacell Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Wells Fargo's Briacell Therapeutics position peaked at $360 in Q3 2024.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.